Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that the saturated community-acquired pneumonia (CAP) drug market will decline from nearly $1.3 billion in 2001 to $1 billion in 2011. A new Pharmacor report from Decision Resources, Community- Acquired Pneumonia, concludes that generic erosion will be a major factor in the sales decrease.

(Photo: NewsCom: )

"There are many drugs available to treat community-acquired pneumonia," said Margaret Jorgensen, Ph.D., analyst at Decision Resources. "Because of this market saturation, the growth potential of emerging agents to treat community-acquired pneumonia is limited. Many agents on the market, including penicillins, cephalosporins, macrolides, and fluoroquinolones, already effectively treat the majority of CAP cases. Consequently, multiple agents are competing with each other and with generics for relatively small shares of the CAP market."

Disease Facts-Community-Acquired Pneumonia

Community-acquired pneumonia is one of the leading causes of death due to infection and the seventh-leading cause of death overall in the United States. Worldwide, CAP is associated with significant morbidity, mortality, and utilization of health service resources. Despite advances in antibiotic therapies, mortality rates, particularly among the elderly, remain relatively high. In addition, resistance to commonly used antibiotics is increasing.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Community-Acquired Pneumonia is an Infectious Disease report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Expanding Multi-Resistant HIV Populationin Need of New Classes of Drugs

View Now